Clinical trial NCT02585804: Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Official title: Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: "The TRANSLATE Study"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Focal Segmental Glomerulosclerosis
Keywords: FSGS, SGLT2, chronic kidney disease, GFR, proteinuria
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
Collaborators: name: AstraZeneca
name: University of Toronto
name: Toronto General Hospital
First posted: 2015-10-23
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk factor for end stage renal failure. Current non-immunological FSGS therapies include the use of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), to reduce intraglomerular hypertension. Unfortunately, these agents lead to incomplete renal protection. The aim of the current study is to determine whether the addition of novel sodium glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced intraglomerular pressure and suppression of proteinuria. We hypothesize that combination therapy of SGLT2i drugs and conventional RAASi results in additive renal protective effects in FSGS patients. A further goal is to examine mechanisms of SGLT2 inhibition by measuring renal hemodynamic function and sodium handling. Kidney function will be assessed in FSGS patients before and after an 8 week treatment with SGLT2i dapagliflozin.

Detailed description: FSGS and diabetic nephropathy may have common pathogenic mechanisms, that are mediated by intraglomerular hypertension, leading to hyperfiltration and proteinuria. Given that SGLT2i corrects early hemodynamic abnormalities in patients with diabetes, our aim is to determine if a similar benefit may extend to patients with FSGS. Based on previous experimental and clinical data, we hypothesize that SGLT2i will improve renal hemodynamic abnormalities characteristic of FSGS that promote renal injury and proteinuria.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects diagnosed with FSGS ≥1 month prior to informed consent
* eGFR≥45 ml/min/1.73m2
* Age 18 years or greater
* No history of diabetes
* Body Mass Index (BMI) 18.5 - 45.0 kg/ m2
* Blood pressure ≥ 100/60 at screening
* Stable therapy with either an ACEi or angiotensin II receptor blocker or direct renin inhibitor for \> 1 month
* \>30 mg/day and \<6 g/day of proteinuria unless the patient is not a candidate for immunosuppressive therapy

Exclusion Criteria:

* Leukocyte and/or nitrite positive urinalysis that is untreated;
* History of organ transplantation, cancer, liver disease;
* Bariatric surgery or other gastrointestinal surgeries that induce chronic malabsorption within the past two years;
* Current treatment with systemic corticosteroids, calcineurin inhibitors, or other immunosuppressant medications;
* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;
* Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not practising an acceptable method of birth control;
* Participation in another therapeutic trial with an investigational drug within 30 days prior to informed consent;
* Alcohol or drug abuse within three months prior to informed consent that would interfere with trial participation or any ongoing clinical condition that would jeopardize subject safety or study compliance based on investigator judgement;
* Liver disease, defined by serum levels of alanine transaminase, aspartate transaminase, or alkaline phosphatase \>3 x upper limit of normal as determined during screening;
* Cardiac, lung or peripheral vascular disease or stroke;
* Pancreas, pancreatic islet cells or renal transplant recipient;
* Medical history of cancer or treatment for cancer in the last five years prior to screening;
* History of allergy or angioedema with RAAS inhibitor exposure;
* Kidney disease due primarily to another condition aside from FSGS;

Primary outcomes:
measure: The change in Glomerular Filtration Rate (GFR) After an 8 week treatment with dapagliflozin
timeFrame: Before and after an 8 week treatment with dapagliflozin
Secondary outcomes:
measure: The change in Effective Renal Plasma Flow (ERPF) After an 8 week treatment with dapagliflozin
timeFrame: Before and after an 8 week treatment with dapagliflozin
measure: The change in Blood Pressure After an 8 week treatment with dapagliflozin
timeFrame: Before and after 8 weeks of treatment with dapagliflozin
measure: The change in albuminuria after 8 weeks of treatment with dapagliflozin
timeFrame: Before and after 8 weeks of treatment with dapagliflozin
measure: The change in urinary vasoactive mediators after 8 weeks of treatment with dapagliflozin
timeFrame: Before and after 8 weeks of treatment with dapagliflozin
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Renal Physiology Laboratory, University Health Network
state: Ontario
Study officials:
References: